Purpose NUT carcinoma (NC) is a solid tumor caused by the rearrangement of NUTM1 that usually develops in midline structures, such as the thorax. No standard treatment has been established despite high lethality. Thus, we investigated whether targeting the junction region of NUTM1 fusion breakpoints could serve as a potential treatment option for NC.
Materials and Methods We designed and evaluated a series of small interfering RNAs (siRNAs) targeting the junction region of BRD4-NUTM1 fusion (B4N), the most common form of NUTM1 fusion. Droplet digital polymerase chain reaction using the blood of patients was also tested to evaluate the treatment responses by the junction sequence of the B4N fusion transcripts.
Results As expected, the majority of NC fusion types were B4N (12 of 18, 67%). B4N fusion-specific siRNA treatment on NC cells showed specific inhibitory effects on the B4N fusion transcript and fusion protein without affecting the endogenous expression of the parent genes, resulting in decreased relative cell growth and attenuation of tumor size. In addition, the fusion transcript levels in platelet-rich-plasma samples of the NC patients with systemic metastasis showed a negative correlation with therapeutic effect, suggesting its potential as a measure of treatment responsiveness.
Conclusion This study suggests that tumor-specific sequences could be used to treat patients with fusion genes as part of precision medicine for a rare but deadly disease.
Citations
Citations to this article as recorded by
Indirect targeting of MYC and direct targeting in combination with chemotherapies are more effective than direct mono-targeting in triple negative breast cancer Negesse Mekonnen, Hobin Yang, Nirmal Rajasekaran, Kyoung Song, Yoon-La Choi, Young Kee Shin Translational Oncology.2025; 51: 102204. CrossRef
NUT-midline carcinoma of the lung with rare BRD3-NUTM1 fusion Prerana Jha, Vaishakhi Trivedi, Nandini Menon, Minit Shah, Irene A George, Rohit Mishra, Trupti Pai, Fuzail Ahmad, Venkataramanan Ramachandran, Vanita Noronha, Kumar Prabhash, Prashant Kumar Cancer Research, Statistics, and Treatment.2024; 7(1): 110. CrossRef
Purpose
To find biomarkers for disease, there have been constant attempts to investigate the genes that differ from those in the disease groups. However, the values that lie outside the overall pattern of a distribution, the outliers, are frequently excluded in traditional analytical methods as they are considered to be ‘some sort of problem.’ Such outliers may have a biologic role in the disease group. Thus, this study explored new biomarker using outlier analysis, and verified the suitability of therapeutic potential of two genes (TM4SF4 and LRRK2).
Materials and Methods
Modified Tukey’s fences outlier analysis was carried out to identify new biomarkers using the public gene expression datasets. And we verified the presence of the selected biomarkers in other clinical samples via customized gene expression panels and tissue microarrays. Moreover, a siRNA-based knockdown test was performed to evaluate the impact of the biomarkers on oncogenic phenotypes.
Results TM4SF4 in lung cancer and LRRK2 in breast cancer were chosen as candidates among the genes derived from the analysis. TM4SF4 and LRRK2 were overexpressed in the small number of samples with lung cancer (4.20%) and breast cancer (2.42%), respectively. Knockdown of TM4SF4 and LRRK2 suppressed the growth of lung and breast cancer cell lines. The LRRK2 overexpressing cell lines were more sensitive to LRRK2-IN-1 than the LRRK2 under-expressing cell lines
Conclusion
Our modified outlier-based analysis method has proved to rescue biomarkers previously missed or unnoticed by traditional analysis showing TM4SF4 and LRRK2 are novel target candidates for lung and breast cancer, respectively.
Citations
Citations to this article as recorded by
TM4SF19—A New Biomarker for Diagnosis and Prognosis of Bladder Urothelial Carcinoma 蕴博 刘 Advances in Clinical Medicine.2024; 14(02): 3616. CrossRef
Validating linalool as a potential drug for breast cancer treatment based on machine learning and molecular docking Qian Zhang, Dengfeng Chen Drug Development Research.2024;[Epub] CrossRef
DeepDRA: Drug repurposing using multi-omics data integration with autoencoders Taha Mohammadzadeh-Vardin, Amin Ghareyazi, Ali Gharizadeh, Karim Abbasi, Hamid R. Rabiee, Amgad Muneer PLOS ONE.2024; 19(7): e0307649. CrossRef
TM4SF4 is a diagnostic biomarker accelerating progression of papillary thyroid cancer via AKT pathway Lizhi Lin, Jialiang Wen, Tiansheng Xu, Yuhao Si Cancer Biology & Therapy.2024;[Epub] CrossRef
Three Members of Transmembrane-4-Superfamily, TM4SF1, TM4SF4, and TM4SF5, as Emerging Anticancer Molecular Targets against Cancer Phenotypes and Chemoresistance Nur Syafiqah Rahim, Yuan Seng Wu, Maw Shin Sim, Appalaraju Velaga, Srinivasa Reddy Bonam, Subash C. B. Gopinath, Vetriselvan Subramaniyan, Ker Woon Choy, Sin-Yeang Teow, Ismail M. Fareez, Chandramathi Samudi, Shamala Devi Sekaran, Mahendran Sekar, Rhanye Pharmaceuticals.2023; 16(1): 110. CrossRef
Quantitative Analysis on Molecular Characteristics Evolution of Gastric Cancer Progression and Prognosis Yeting Hu, Xiaoqin Lv, Wenwu Wei, Xiang Li, Kaixuan Zhang, Linlin Zhu, Tao Gan, Hongjuan Zeng, Jinlin Yang, Nini Rao Advanced Biology.2023;[Epub] CrossRef
Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis Muttanagouda Giriyappagoudar, Basavaraj Vastrad, Rajeshwari Horakeri, Chanabasayya Vastrad Biomedicines.2023; 11(12): 3109. CrossRef
Parkinson’s disease and cancer: a systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender Joon Yan Selene Lee, Jing Han Ng, Seyed Ehsan Saffari, Eng-King Tan Aging.2022; 14(5): 2148. CrossRef
Identification of autophagy-related biomarkers in patients with pulmonary arterial hypertension based on bioinformatics analysis Zhisong Yang, Li Zhou, Haiyan Ge, Weimin Shen, Lin Shan Open Medicine.2022; 17(1): 1148. CrossRef
Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation Mingfeng Yu, Yi Long, Yuchao Yang, Manjun Li, Theodosia Teo, Benjamin Noll, Stephen Philip, Shudong Wang European Journal of Medicinal Chemistry.2021; 218: 113391. CrossRef
Shifting Gears in Precision Oncology—Challenges and Opportunities of Integrative Data Analysis Ka-Won Noh, Reinhard Buettner, Sebastian Klein Biomolecules.2021; 11(9): 1310. CrossRef
Purpose
The discoidin domain-containing receptor tyrosine kinase 2 (DDR2) is known to contain mutations in a small subset of patients with squamous cell carcinomas (SCC) of the lung. Studying the DDR2 mutations in patients with SCC of the lung would advance our understanding and guide the development of therapeutic strategies against lung cancer.
Materials and Methods
We selected 100 samples through a preliminary genetic screen, including specimens from biopsies and surgical resection, and confirmed SCC by histologic examination. DDR2 mutations on exons 6, 15, 16, and 18 were analyzed by Sanger sequencing of formalin-fixed, paraffin-embedded tissue samples. The functional effects of novel DDR2 mutants were confirmed by in vitro assays.
Results
We identified novel somatic mutations of DDR2 in two of the 100 SCC samples studied. One mutation was c.1745T>A (p.V582E) and the other was c.1784T>C (p.L595P), and both were on exon 15. Both patients were smokers and EGFR/KRAS/ALK-triple negative. The expression of the mutant DDR2 induced activation of DDR2 by the collagen ligand and caused enhanced cell growth and tumor progression. Moreover, dasatinib, a DDR2 inhibitor, showed potential efficacy against DDR2 L595P mutant–bearing cells.
Conclusion
Our results suggest that a mutation in DDR2 occurs naturally with a frequency of about 2% in Korean lung SCC patients. In addition, we showed that each of the novel DDR2 mutations were located in a kinase domain and induced an increase in cell proliferation rate.
Citations
Citations to this article as recorded by
Potentially functional variants of PARK7 and DDR2 in ferroptosis‐related genes predict survival of non‐small cell lung cancer patients Huilin Wang, Hongliang Liu, Xiaozhun Tang, Guojun Lu, Sheng Luo, Mulong Du, David C. Christiani, Qingyi Wei International Journal of Cancer.2025; 156(4): 744. CrossRef
Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer Yanning Sun, Li Ma, Xiaofei Zhang, Zhaoxia Wang OncoTargets and Therapy.2024; Volume 17: 1095. CrossRef
Discoidin Domain Receptor 2: A New Target in Cancer Xiaoxiao Xu, Tong Yu, Zhenxing Wang Oncology Research and Treatment.2022; 45(4): 205. CrossRef
Unearthing novel fusions as therapeutic targets in solid tumors using targeted RNA sequencing Sungbin An, Hyun Hee Koh, Eun Sol Chang, Juyoung Choi, Ji-Young Song, Mi-Sook Lee, Yoon-La Choi Frontiers in Oncology.2022;[Epub] CrossRef
Squamous cell lung cancer: Current landscape and future therapeutic options Sally C.M. Lau, Yuanwang Pan, Vamsidhar Velcheti, Kwok Kin Wong Cancer Cell.2022; 40(11): 1279. CrossRef
Complex roles of discoidin domain receptor tyrosine kinases in cancer V. Mehta, H. Chander, A. Munshi Clinical and Translational Oncology.2021; 23(8): 1497. CrossRef
The Yin and Yang of Discoidin Domain Receptors (DDRs): Implications in Tumor Growth and Metastasis Development Sandra Majo, Patrick Auguste Cancers.2021; 13(7): 1725. CrossRef
Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing Charles Ricordel, Alexandra Lespagnol, Francisco Llamas-Gutierrez, Marie de Tayrac, Mallorie Kerjouan, Alice Fievet, Houda Hamdi-Rozé, Amyrat Aliouat, Benoit Desrues, Jean Mosser, Hervé Léna Clinical Lung Cancer.2018; 19(2): 163. CrossRef
Extracellular matrix functions in lung cancer Martin Götte, Ilona Kovalszky Matrix Biology.2018; 73: 105. CrossRef
Subjecting appropriate lung adenocarcinoma samples to next‐generation sequencing‐based molecular testing: challenges and possible solutions Weihua Li, Tian Qiu, Yun Ling, Shugeng Gao, Jianming Ying Molecular Oncology.2018; 12(5): 677. CrossRef
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells Ugo Testa, Germana Castelli, Elvira Pelosi Cancers.2018; 10(8): 248. CrossRef
Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients Zahra Fathi, Seyed Ali Javad Mousavi, Raheleh Roudi, Farideh Ghazi, Sumitra Deb PLOS ONE.2018; 13(7): e0200633. CrossRef
Eun Jin Heo, Young Jae Cho, William Chi Cho, Ji Eun Hong, Hye-Kyung Jeon, Doo-Yi Oh, Yoon-La Choi, Sang Yong Song, Jung-Joo Choi, Duk-Soo Bae, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Woong-Yang Park, Byoung-Gie Kim, Jeong-Won Lee
Cancer Res Treat. 2017;49(4):915-926. Published online January 4, 2017
Purpose
Patient-derived tumor xenografts (PDXs) can provide more reliable information about tumor biology than cell line models. We developed PDXs for epithelial ovarian cancer (EOC) that have histopathologic and genetic similarities to the primary patient tissues and evaluated their potential for use as a platform for translational EOC research.
Materials and Methods
We successfully established PDXs by subrenal capsule implantation of primary EOC tissues into female BALB/C-nude mice. The rate of successful PDX engraftment was 48.8% (22/45 cases). Hematoxylin and eosin staining and short tandem repeat analysis showed histopathological and genetic similarity between the PDX and primary patient tissues.
Results
Patients whose tumors were successfully engrafted in mice had significantly inferior overall survival when compared with those whose tumors failed to engraft (p=0.040). In preclinical tests of this model, we found that paclitaxel-carboplatin combination chemotherapy significantly deceased tumor weight in PDXs compared with the control treatment (p=0.013). Moreover, erlotinib treatment significantly decreased tumor weight in epidermal growth factor receptor–overexpressing PDX with clear cell histology (p=0.023).
Conclusion
PDXs for EOC with histopathological and genetic stability can be efficiently developed by subrenal capsule implantation and have the potential to provide a promising platform for future translational research and precision medicine for EOC.
Citations
Citations to this article as recorded by
Patient-derived xenograft models: Current status, challenges, and innovations in cancer research Min qi Liu, Xiaoping Yang Genes & Diseases.2025; : 101520. CrossRef
Establishment and characterization of ovarian clear cell carcinoma patient-derived xenografts Joseph J. Caumanns, Shang Li, Gert J. Meersma, Evelien W. Duiker, Ate G. J. van der Zee, G. Bea A. Wisman, Steven de Jong Scientific Reports.2025;[Epub] CrossRef
The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression Yoo-Young Lee, Ji-Yoon Ryu, Young-Jae Cho, Ju-Yeon Choi, Jung-Joo Choi, Chel Hun Choi, Jason K. Sa, Jae Ryoung Hwang, Jeong-Won Lee Cancer Cell International.2024;[Epub] CrossRef
Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience Ruri Nishie, Tomohito Tanaka, Kensuke Hirosuna, Shunsuke Miyamoto, Hikaru Murakami, Hiromitsu Tsuchihashi, Akihiko Toji, Shoko Ueda, Natsuko Morita, Sousuke Hashida, Atsushi Daimon, Shinichi Terada, Hiroshi Maruoka, Hiromi Konishi, Yuhei Kogata, Kohei Tan Journal of Clinical Medicine.2024; 13(9): 2718. CrossRef
Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer Byumseok Koh, Ji-Yoon Ryu, Joseph J. Noh, Jae Ryoung Hwang, Jung-Joo Choi, Young-Jae Cho, Jiyoon Jang, Jeong Hyeon Jo, Kwangho Lee, Jeong-Won Lee Gynecologic Oncology.2024; 188: 60. CrossRef
Recent advances in lung cancer organoid (tumoroid) research (Review) Qiang Zhang, Mingyang Zhang Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Patient‐derived xenograft model in colorectal cancer basic and translational research Xiaofeng Liu, Zechang Xin, Kun Wang Animal Models and Experimental Medicine.2023; 6(1): 26. CrossRef
Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment Kenneth K. W. To, Ka M. Cheung, William C. S. Cho Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7217. CrossRef
Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer Chi-Son Chang, Ji-Yoon Ryu, June-Kuk Choi, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Joseph J. Noh, Chan Mi Lee, Ji Eun Won, Hee Dong Han, Jeong-Won Lee Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Molecular Biology of Pediatric and Adult Ovarian Germ Cell Tumors: A Review Mariana Tomazini Pinto, Gisele Eiras Martins, Ana Glenda Santarosa Vieira, Janaina Mello Soares Galvão, Cristiano de Pádua Souza, Carla Renata Pacheco Donato Macedo, Luiz Fernando Lopes Cancers.2023; 15(11): 2990. CrossRef
Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice Mingtang Zeng, Zijing Ruan, Jiaxi Tang, Maozhu Liu, Chengji Hu, Ping Fan, Xinhua Dai Cancer Cell International.2023;[Epub] CrossRef
Research Progress of PD-1/PD-L1 Inhibitors in Immunotherapy of Prostate Cancer 佳慧 吴 Advances in Clinical Medicine.2023; 13(06): 10496. CrossRef
Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma Jae Ryoung Hwang, Young-Jae Cho, Ji-Yoon Ryu, Ju-Yeon Choi, Jung-Joo Choi, Jason K. Sa, Hyun-Soo Kim, Jeong-Won Lee Biomedicine & Pharmacotherapy.2023; 168: 115792. CrossRef
Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model Yukari Oda, Kaoru Niimi, Kosuke Yoshida, Satoshi Tamauchi, Akira Yokoi, Yuko Yasui, Yuki Nishiko, Mayu Shibata, Yusuke Shimizu, Masato Yoshihara, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kimihiro Nishino, Eiko Yamamoto, Hiroaki Kajiyama BMC Cancer.2023;[Epub] CrossRef
Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models Ha-Yeon Shin, Eun-ju Lee, Wookyeom Yang, Hyo Sun Kim, Dawn Chung, Hanbyoul Cho, Jae-Hoon Kim Cancers.2022; 14(3): 829. CrossRef
Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine Christine Yee, Kristie-Ann Dickson, Mohammed N. Muntasir, Yue Ma, Deborah J. Marsh Frontiers in Bioengineering and Biotechnology.2022;[Epub] CrossRef
Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer Jung-In Shim, Ji-Yoon Ryu, Soo Young Jeong, Young-Jae Cho, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jason K. Sa, Jeong-Won Lee Gynecologic Oncology.2022; 165(2): 270. CrossRef
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application Alessandra Ciucci, Marianna Buttarelli, Anna Fagotti, Giovanni Scambia, Daniela Gallo Cellular and Molecular Life Sciences.2022;[Epub] CrossRef
Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma Joseph J. Noh, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae Ryoung Hwang, Ju-Yeon Choi, Jeong-Won Lee Clinical Cancer Research.2022; 28(17): 3850. CrossRef
Harnessing preclinical models for the interrogation of ovarian cancer Tianyu Qin, Junpeng Fan, Funian Lu, Li Zhang, Chen Liu, Qiyue Xiong, Yang Zhao, Gang Chen, Chaoyang Sun Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef
The Development of a Three-Dimensional Platform for Patient-Derived Ovarian Cancer Tissue Models: A Systematic Literature Review Lusine Sevinyan, Priyanka Gupta, Eirini Velliou, Thumuluru Kavitha Madhuri Cancers.2022; 14(22): 5628. CrossRef
A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report Yunke Huang, Jing Xu, Ke Li, Jing Wang, Yilin Dai, Yu Kang Cancer Management and Research.2021; Volume 13: 2849. CrossRef
Establishment and preclinical application of a patient-derived xenograft model for uterine cancer Soo Young Jeong, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Jae-Ryoung Hwang, Binnari Kim, Yoo-Young Lee, Hyun-Soo Kim, Jeong-Won Lee Gynecologic Oncology.2021; 162(1): 173. CrossRef
Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies Paula Cunnea, Christina Fotopoulou, Jennifer Ploski, Fabian Trillsch, Sven Mahner, Mirjana Kessler Cancers.2021; 13(13): 3349. CrossRef
Methodological aspects of creation of patient-derived tumor xenografts A S Goncharova, A N Shevchenko, I R Dashkova, A E Anisimov Kazan medical journal.2021; 102(5): 694. CrossRef
The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis Jinseong Kim, Man Kyu Shim, Young-Jae Cho, Sangmin Jeon, Yujeong Moon, Jiwoong Choi, Jeongrae Kim, Jaewan Lee, Jeong-Won Lee, Kwangmeyung Kim Biomaterials.2021; 279: 121189. CrossRef
Modeling the Tumor Microenvironment of Ovarian Cancer: The Application of Self-Assembling Biomaterials Ana Karen Mendoza-Martinez, Daniela Loessner, Alvaro Mata, Helena S. Azevedo Cancers.2021; 13(22): 5745. CrossRef
Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research Magdalena Cybula, Lin Wang, Luyao Wang, Ana Luiza Drumond-Bock, Katherine M. Moxley, Doris M. Benbrook, Camille Gunderson-Jackson, Maria J. Ruiz-Echevarria, Resham Bhattacharya, Priyabrata Mukherjee, Magdalena Bieniasz Cancers.2021; 13(24): 6288. CrossRef
Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects Sharmin Seraj, Young Jae Cho, Jeong-Won Lee, Hyung Jun Ahn Biochemical Pharmacology.2020; 171: 113735. CrossRef
The fidelity of cancer cells in PDX models: Characteristics, mechanism and clinical significance Jiahao Shi, Yongyun Li, Renbing Jia, Xianqun Fan International Journal of Cancer.2020; 146(8): 2078. CrossRef
KSP siRNA/paclitaxel-loaded PEGylated cationic liposomes for overcoming resistance to KSP inhibitors: Synergistic antitumor effects in drug-resistant ovarian cancer Jinju Lee, Young Jae Cho, Jeong-Won Lee, Hyung Jun Ahn Journal of Controlled Release.2020; 321: 184. CrossRef
A patient‐derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma Tomoki Yamano, Shuji Kubo, Naohiro Tomita Cancer Medicine.2020; 9(10): 3337. CrossRef
Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer E Sun Paik, Tae-Hyun Kim, Young Jae Cho, Jiyoon Ryu, Jung-Joo Choi, Yoo-Young Lee, Tae-Joong Kim, Chel-Hun Choi, Woo Young Kim, Jason K. Sa, Jin-Ku Lee, Byoung-Gie Kim, Duk-Soo Bae, Hee Dong Han, Hyung Jun Ahn, Jeong-Won Lee Scientific Reports.2020;[Epub] CrossRef
A Biobank of Colorectal Cancer Patient-Derived Xenografts Suad M. Abdirahman, Michael Christie, Adele Preaudet, Marie C. U. Burstroem, Dmitri Mouradov, Belinda Lee, Oliver M. Sieber, Tracy L. Putoczki Cancers.2020; 12(9): 2340. CrossRef
Epithelial/mesenchymal heterogeneity of high‐grade serous ovarian carcinoma samples correlates with miRNA let‐7 levels and predicts tumor growth and metastasis Evgeny Chirshev, Nozomi Hojo, Antonella Bertucci, Linda Sanderman, Anthony Nguyen, Hanmin Wang, Tise Suzuki, Emmanuel Brito, Shannalee R. Martinez, Christine Castañón, Saied Mirshahidi, Marcelo E. Vazquez, Pamela Wat, Kerby C. Oberg, Yevgeniya J. Ioffe, J Molecular Oncology.2020; 14(11): 2796. CrossRef
Human-Derived Model Systems in Gynecological Cancer Research Kadi Lõhmussaar, Matteo Boretto, Hans Clevers Trends in Cancer.2020; 6(12): 1031. CrossRef
Spontaneous and Induced Animal Models for Cancer Research Anca Onaciu, Raluca Munteanu, Vlad Cristian Munteanu, Diana Gulei, Lajos Raduly, Richard-Ionut Feder, Radu Pirlog, Atanas G. Atanasov, Schuyler S. Korban, Alexandru Irimie, Ioana Berindan-Neagoe Diagnostics.2020; 10(9): 660. CrossRef
Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer Joseph J. Noh, Myeong-Seon Kim, Young-Jae Cho, Soo-Young Jeong, Yoo-Young Lee, Ji-Yoon Ryu, Jung-Joo Choi, Illju Bae, Zhaoyan Wu, Byoung-Gie Kim, Jae Ryoung Hwang, Jeong-Won Lee Pharmaceutics.2020; 12(10): 987. CrossRef
Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures Sofia Abreu, Fernanda Silva, Rita Mendes, Teresa F. Mendes, Marta Teixeira, Vítor E. Santo, Erwin R. Boghaert, Ana Félix, Catarina Brito Scientific Reports.2020;[Epub] CrossRef
Chloroquine reverses chemoresistance via upregulation of p21WAF1/CIP1 and autophagy inhibition in ovarian cancer Jae Ryoung Hwang, Woo Young Kim, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Soo Young Jeong, Myeong-Sun Kim, Ji Hye Kim, E. Sun Paik, Yoo-Young Lee, Hee-Dong Han, Jeong-Won Lee Cell Death & Disease.2020;[Epub] CrossRef
Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma Eun Byeol Jo, Doopyo Hong, Young Sang Lee, Hyunjoo Lee, Jae Berm Park, Sung Joo Kim Translational Oncology.2019; 12(2): 269. CrossRef
Platinum Resistance in Ovarian Cancer: Role of DNA Repair Giovanna Damia, Massimo Broggini Cancers.2019; 11(1): 119. CrossRef
Establishment of patient‐derived xenograft model in ovarian cancer and its influence factors analysis Jianfa Wu, Yunxi Zheng, Qi Tian, Ming Yao, Xiaofang Yi Journal of Obstetrics and Gynaecology Research.2019; 45(10): 2062. CrossRef
Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models Seiji Okada, Kulthida Vaeteewoottacharn, Ryusho Kariya Cells.2019; 8(8): 889. CrossRef
Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research Akira Inoue, Angela K. Deem, Scott Kopetz, Timothy P. Heffernan, Giulio F. Draetta, Alessandro Carugo Cancers.2019; 11(9): 1321. CrossRef
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers Jason K. Sa, Jae Ryoung Hwang, Young-Jae Cho, Ji-Yoon Ryu, Jung-Joo Choi, Soo Young Jeong, Jihye Kim, Myeong Seon Kim, E. Sun Paik, Yoo-Young Lee, Chel Hun Choi, Tae-Joong Kim, Byoung-Gie Kim, Duk-Soo Bae, Yeri Lee, Nam-Gu Her, Yong Jae Shin, Hee Jin Cho, Genome Biology.2019;[Epub] CrossRef
The latest animal models of ovarian cancer for novel drug discovery Elizabeth Magnotti, Wayne A. Marasco Expert Opinion on Drug Discovery.2018; 13(3): 249. CrossRef
Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells Ugo Testa, Eleonora Petrucci, Luca Pasquini, Germana Castelli, Elvira Pelosi Medicines.2018; 5(1): 16. CrossRef
NIRF Optical/PET Dual-Modal Imaging of Hepatocellular Carcinoma Using Heptamethine Carbocyanine Dye Caiqin Zhang, Yong Zhao, Ningning Zhao, Dengxu Tan, He Zhang, Xue Chen, Hai Zhang, Jiaze An, Changhong Shi, Mengbin Li Contrast Media & Molecular Imaging.2018; 2018: 1. CrossRef
Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models Kyung Jin Eoh, Young Shin Chung, So Hyun Lee, Sun-Ae Park, Hee Jung Kim, Wookyeom Yang, In Ok Lee, Jung-Yun Lee, Hanbyoul Cho, Doo Byung Chay, Sunghoon Kim, Sang Wun Kim, Jae-Hoon Kim, Young Tae Kim, Eun Ji Nam Cancer Research and Treatment.2018; 50(3): 956. CrossRef
CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer Yeongseon Byeon, Jeong-Won Lee, Whan Soo Choi, Ji Eun Won, Ga Hee Kim, Min Gi Kim, Tae In Wi, Jae Myeong Lee, Tae Heung Kang, In Duk Jung, Young-Jae Cho, Hyung Jun Ahn, Byung Cheol Shin, Young Joo Lee, Anil K. Sood, Hee Dong Han, Yeong-Min Park Cancer Research.2018; 78(21): 6247. CrossRef